One of the most significant developments in clinical pharmacology over the past decade has been the emergence of concentration-QTc (C-QTc) analyses as a key tool for evaluating cardiac safety. By integrating pharmacokinetics, electrocardiography, and quantitative modeling, these analyses have transformed how scientists assess the relationship between drug exposure and cardiac response.
As a PK scientist, one aspect of my work involves understanding how drug exposure influences both efficacy and safety. What makes concentration-QTc analyses particularly interesting to me is that they apply the same exposure-response principles used throughout clinical pharmacology to one of the most important safety questions in drug development: can increasing drug exposure affect cardiac repolarization?
